Blog

Justin Stebbing: Excited to be a communicating author with benefits to patients with “cold tumours”

Justin Stebbing/healthpost.in

Jul 4, 2024, 15:34

Justin Stebbing: Excited to be a communicating author with benefits to patients with “cold tumours”

“Really excited to be part of this/communicating author with benefits to patients with ‘cold tumours’.”

Source:

Justin Stebbing: Excited to be a communicating author with benefits to patients with "cold tumours"

Justin Stebbing is a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at Anglia Ruskin University (ARU), Cambridge. He was appointed the first NIHR oncology professor in 2011. He is editor-in-chief of Nature’s cancer journal Oncogene. Prof. Stebbing has published over 700 peer-reviewed papers in leading academic journals. He is a member of the American Society for Clinical Investigation, a fellow of the Royal College of Physicians, and the Royal College of Pathologists, and sits on many advisory boards. He is on the Editorial Board of OncoDaily.

Anglia Ruskin University botensilimab plus balstilimab cancer cold tumours communicating author Imperial College Justin Stebbing OncoDaily Oncology Research

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage